Journal of Pain and Symptom Management
Volume 27, Issue 3 , Pages 268-273 , March 2004

Treatment of opioid-induced delirium with acetylcholinesterase inhibitors: a case report

  • Neal Slatkin, MD, DABPM

      Affiliations

    • Corresponding Author InformationAddress reprint requests to: Neal Slatkin, MD, Supportive Care, Pain and Palliative Medicine, City of Hope, 1500 E. Duarte Road, Duarte, CA 91010, USA.
    • ,
  • Michelle Rhiner, RN, MSN, NP, CHPN

,Accepted 14 July 2003.

References 

  1. Lawlor PG, Gagnon B, Mancini IL, et al.  Occurrence, causes, and outcome of delirium in patients with advanced cancer: a prospective study. Arch Intern Med. 2000;160(6):786–794
  2. Morita T, Tei Y, Tsunoda J, et al.  Underlying pathologies and their associations with clinical features in terminal delirium of cancer patients. J Pain Symptom Manage. 2001;22(6):997–1006
  3. Tuma R, DeAngelis LM. Altered mental status in patients with cancer. Arch Neurol. 2000;57(12):1727–1731
  4. Bruera E, Neumann CM. Opioid toxicities—assessment and management. In:  Max M editors. Pain 1999—an updated review: IASP Refresher Courses on Pain Management. Seattle: IASP Press; 1999;
  5. Bruera E, Franco JJ, Maltoni M, et al.  Changing pattern of agitated impaired mental status in patients with advanced cancer associated with cognitive monitoring, hydration, and opioid rotation. J Pain Symptom Manage. 1995;10:287–291
  6. Gagnon B, Bielech M, Watanabe S, et al.  The use of intermittent subcutaneous injections of oxycodone for opioid rotation in patients with cancer pain. Support Care Cancer. 1999;7(4):265–270
  7. Maddocks I, Somogyi A, Abbott F, et al.  Attenuation of morphine-induced delirium in palliative care by substitution with infusion of oxycodone. J Pain Symptom Manage. 1996;12(3):182–189
  8. Slatkin NE, Rhiner M, Bolton TM. Donepezil in the treatment of opioid-induced sedation: report of six cases. J Pain Symptom Manage. 2001;21(5):425–438
  9. Slatkin NE, Rhiner M. Treatment of opiate related sedation: utility of cholinesterase inhibitors. J Supp Oncol. 2003;1(1):53–63
  10. Weinstock M, Davidson JT, Rosin AJ, et al.  Effect of physostigmine on morphine-induced postoperative pain and somnolence. Br J Anaesth. 1982;54(4):429–434
  11. Sternbach H, State R. Antibiotics: neuropsychiatric effects and psychotropic interactions. Harvard Rev Psychiatry. 1997;5(4):214–226
  12. Breitbart W, Rosenfeld B, Roth A, et al.  The Memorial Delirium Assessment Scale. J Pain Symptom Manage. 1997;13(3):128–137
  13. Zajecka J, Fawcett J, Amsterdam J, et al.  Safety of abrupt discontinuation of fluoxetine: a randomized, placebo-controlled study. J Clin Psychopharmacol. 1998;18(3):193–197
  14. Bruera E, Franco JJ, Maltoni M, et al.  Changing pattern of agitated impaired mental status in patients with advanced cancer: association with cognitive monitoring, hydration, and opioid rotation. J Pain Symptom Manage. 1995;10(4):287–291
  15. Triggle DJ, Mitchell JM, Filler R. The pharmacology of physostigmine. CNS Drug Rev. 1998;4(2):87–136
  16. Jones BE. The organization of central cholinergic systems and their functional importance in sleep-waking states. Prog Brain Res. 1993;98:61–71
  17. Sarter M, Bruno JP. Cognitive functions of cortical acetylcholine: toward a unifying hypothesis. Brain Res Brain Res Rev. 1997;23(1–2):28–46
  18. Perry E, Walker M, Grace J, et al.  Acetylcholine in mind: a neurotransmitter correlate of consciousness?. Trends Neurosci. 1999;22(6):273–280
  19. Muir JL, Page KJ, Sirinathsinghji DJ, et al.  Excitotoxic lesions of basal forebrain cholinergic neurons: effects on learning, memory and attention. Behav Brain Res. 1993;57(2):123–131
  20. Molchan SE, Martinez RA, Hill JL, et al.  Increased cognitive sensitivity to scopolamine with age and a perspective on the scopolamine model. Brain Res Brain Res Rev. 1992;17(3):215–226
  21. Cheal ML. Scopolamine disrupts maintenance of attention rather than memory processes. Behav Neural Biol. 1981;33(2):163–187
  22. Sarter M, Bruno JP, Turchi J. Basal forebrain afferent projections modulating cortical acetylcholine, attention, and implications for neuropsychiatric disorders. Ann NY Acad Sci. 1999;877:368–382
  23. Kaufer DI, Cummings JL, Christine D. Effect of tacrine on behavioral symptoms in Alzheimer's disease: an open-label study. J Geriatr Psychiatry Neurol. 1996;9:1–6
  24. Feldman H, Gauthier S, Hecker J, et al.  A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology. 2001;57(4):613–620
  25. Reading PJ, Luce AK, McKeith IG. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord. 2001;16(6):1171–1174
  26. Tariot PN, Solomon PR, Morris JC, et al.  A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology. 2000;54(12):2269–2276
  27. Aizawa K, Kanai T, Saikawa Y, et al.  A novel approach to the prevention of postoperative delirium in the elderly after gastrointestinal surgery. Surg Today. 2002;32(4):310–314
  28. Lydic R, Baghdoyan HA. Pedunculopontine stimulation alters respiration and increases ACh release in the pontine reticular formation. Am J Physiol. 1993;264(3 Pt 2):R544–R554
  29. Lydic R, Keifer JC, Baghdoyan HA, et al.  Microdialysis of the pontine reticular formation reveals inhibition of acetylcholine release by morphine. Anesthesiology. 1993;79(5):1003–1012
  30. Baghdoyan HA, Monaco AP, Rodrigo-Angulo ML, et al.  Microinjection of neostigmine into the pontine reticular formation of cats enhances desynchronized sleep signs. J Pharmacol Exp Ther. 1984;231(1):173–180
  31. Baghdoyan HA, Lydic R, Callaway CW, et al.  The carbachol-induced enhancement of desynchronized sleep signs is dose dependent and antagonized by centrally-administered atropine. Neuropsychopharmacology. 1989;2(1):67–79
  32. Hobson JA, McCarley RW, Wyzinski PW. Sleep cycle oscillation: reciprocal discharge by two brainstem neuronal groups. Science. 1975;189(4196):55–58
  33. Tune LE, Damlouji NF, Holland A, et al.  Association of postoperative delirium with raised serum levels of anticholinergic drugs. Lancet. 1981;2(8248):651–653
  34. Flacker JM, Cummings V, Mach JR, et al.  The association of serum anticholinergic activity with delirium in elderly medical patients. Am J Geriatr Psychiatry. 1998;6(1):31–41
  35. Beleslin D, Polak R. Depression by morphine and cholralose of acetylcholine release from the cat's brain. J Physiol (Lond). 1965;177:411–419
  36. Jhamandas K, Sutak M. Morphine-naloxone interaction in the central cholinerigc system: the influence of subcortical lesioning and electrical stimulation. Br J Pharmac. 1976;58:101–107
  37. Yaksh T, Yamamura H. Depression by morphine of the resting and evoked release of [3H]-acetylcholine from the cat caudate nucleus in-vivo. Neuropharmacology. 1977;16:227–233
  38. Rada P, Mark G, Pothos E, et al.  Systemic morphine administration decreases extracellular acetycholine and increases dopamine in the nucleus accumbens of freely moving rats. Neuropharmacology. 1991;30:1133–1136
  39. Domino EF, Wilson AE. Enhanced utilization of brain ACh during morphine withdrawal in the rat. Nature. 1973;243:285–286
  40. Sandor NT, Lendvai B, Vizi ES. Effect of selective opiate antagonists on striatal acetylcholine and dopamine release. Brain Res Bull. 1992;29(3–4):369–373
  41. Mortazavi S, Thompson J, Baghdoyan HA, et al.  Fentanyl and morphine, but not remifentanil, inhibit acetylcholine release in pontine regions modulating arousal. Anesthesiology. 1999;90(4):1070–1077
  42. Kay DC, Eisenstein RB, Jasinski DR. Morphine effects on human REM state, waking state and NREM sleep. Psychopharmacologia. 1969;14(5):404–416
  43. Kay DC. Human sleep during chronic morphine intoxication. Psychopharmacologia. 1975;44(2):117–124
  44. Muir JL, Robbins TW, Everitt BJ. Disruptive effects of muscimol infused into the basal forebrain on conditional discrimination and visual attention: differential interactions with cholinergic mechanisms. Psychopharmacology (Berl). 1992;107(4):541–550
  45. Muir JL, Everitt BJ, Robbins TW. Reversal of visual attentional dysfunction following lesions of the cholinergic basal forebrain by physostigmine and nicotine but not by the 5-HT3 receptor antagonist, ondansetron. Psychopharmacology (Berl). 1995;118(1):82–92
  46. Sitaram N, Moore AM, Gillin JC. The effect of physostigmine on normal human sleep and dreaming. Arch Gen Psychiatry. 1978;35(10):1239–1243
  47. Burns MJ, Linden CH, Graudins A, et al.  A comparison of physostigmine and benzodiazepines for the treatment of anticholinergic poisoning. Ann Emerg Med. 2000;35(4):374–381
  48. Crowell EB, Ketchum JS. The treatment of scopolamine-induced delirium with physostigmine. Clin Pharmacol Ther. 1967;8(3):409–414
  49. Shulman MS, Sandler A, Brebner J. The reversal of epidural morphine induced somnolence with physostigmine. Can Anaesth Soc J. 1984;31(6):678–680
  50. Petersson J, Gordh TE, Hartvig P, et al.  A double-blind trial of the analgesic properties of physostigmine in postoperative patients. Acta Anaesthesiol Scand. 1986;30(4):283–288
  51. Nemirovsky A, Niv D. Cholinergic mechanisms and antinociception. Curr Rev Pain. 1996;1:10–22
  52. Green PG, Kitchen I. Antinociception opioids and the cholinergic system. Prog Neurobiol. 1986;26(2):119–146
  53. Bouaziz H, Tong C, Eisenach JC. Postoperative analgesia from intrathecal neostigmine in sheep. Anesth Analg. 1995;80(6):1140–1144
  54. Schott GD, Loh L. Anticholinesterase drugs in the treatment of chronic pain. Pain. 1984;20(2):201–206

PII: S0885-3924(03)00515-3

doi: 10.1016/j.jpainsymman.2003.07.002

Journal of Pain and Symptom Management
Volume 27, Issue 3 , Pages 268-273 , March 2004

Article Tools